Case report

Late hemorrhagic pseudoseptic arthritis encountered during total knee arthroplasty due to hyaluronic acid viscosupplementation

Jeremy M. Korsh, MD *, William Paul Bassett, MD, Donald R. Polakoff, MD

Department of Orthopaedic Surgery, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA

ARTICLE INFO

Article history:
Received 10 May 2016
Received in revised form 14 August 2016
Accepted 17 August 2016
Available online 12 September 2016

Keywords:
Viscosupplementation
Hyaluronic acid
Pseudoseptic arthritis
Synvisc perisynovitis
Total knee arthroplasty
Case report

ABSTRACT

Osteoarthritis (OA) is the most common form of arthritis and affects approximately one-third of people in the United States aged 65 years and older. Since 2013, the American Academy of Orthopaedic Surgeons has not been able to recommended using hyaluronic acid for patients with symptomatic OA of the knee. Subsequent publications have also cautioned against the use of viscosupplementation based on lack of efficacy and the potential for harm. We present a case of late hemorrhagic pseudoseptic arthritis encountered during TKA due to hyaluronic acid viscosupplementation. Our triad of findings includes (1) acute and chronic inflammatory cells on frozen section, (2) synovitis with hemosiderin deposition, and (3) blackened cartilage with iron deposition on permanent histopathology. Our case is unique in that it shows a previously undescribed late complication of viscosupplementation.

© 2016 The Authors. Published by Elsevier Inc. on behalf of The American Association of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Osteoarthritis (OA) is the most common form of arthritis and affects approximately one-third of people in the United States aged 65 years and older [1]. OA involves the progressive loss of hyaline cartilage with underlying bony changes. Patients with OA suffer from pain, joint effusions, and stiffness. Disease in weight bearing joints (eg, hips and knees) has greater impact. The majority of those affected report movement limitations, and approximately 25% have difficulty with activities of daily living [2]. OA is independently associated with excess mortality, morbidity, as well as high socioeconomic costs [3-5]. Treatment of knee OA is based on many factors including age, severity, and functional status with total knee arthroplasty (TKA) being the most invasive but definitive option.

In 2013, the American Academy of Orthopaedic Surgeons published recommendations for the nonarthroplasty treatment of knee OA [6]. Nonarthroplasty treatment options included conservative measures such as weight loss, pharmacologic treatment with nonsteroidal anti-inflammatory drugs, and procedural treatments including intraarticular injections and arthroscopy. Intraarticular hyaluronic acid (HA) injections, a relatively new modality, aimed to restore the viscoelastic properties of joint fluid in patients with OA. At that time, the authors could not recommend using HA, with a strong strength of evidence, for patients with symptomatic OA of the knee. Where previous guidelines found inconclusive evidence, the 2013 guidelines reviewed 14 studies and found no clinically significant treatment effects for pain, function, or stiffness. Their meta-analysis showed a low likelihood that an appreciable number of patients achieved clinically important benefits.

Subsequent publications have also cautioned against the use of viscosupplementation. A industry-sponsored, multicenter, randomized, double-blind trial of nearly 200 patients with mild to moderate OA found no statistical difference on outcomes measures at 1, 3, and 6 months between intraarticular injection of HA vs placebo [7]. In addition, a systematic review of 19 trials found double-blind, placebo-controlled trials had much smaller treatment effects than open-label trials. Based on assessment of the best evidence, these authors concluded that HA injections offer no
clinically important improvements in pain, function, or stiffness compared to placebo [8]. However, despite this clear lack of efficacy, viscosupplementation remains common especially in areas where there is a higher density of physicians [9].

Recent studies and case reports have revealed a potential harm from viscosupplementation. Both minor and severe inflammatory reactions have been documented and raise safety concerns. The most commonly reported adverse reaction is mild pain or swelling at the site of the injection, which occurs in 1%-20% of patients. This inflammatory response typically begins within 1-72 hours [10-12]. The likelihood of these reactions increases up to 8-fold in those who pursue multiple treatment sessions [12]. Studies have found a varying antibody response to different sources of hyaluronan with Synvisc (Sanofi-Aventis, Bridgewater, NJ) eliciting the greatest immunogenic response in limited animal models [13,14]. However, other products have also been described to cause similar reactions of varying severity [10]. Recently, more long-term risks have also been described. At the 2015 Annual Meeting of the American Association of Hip and Knee Surgeons, one paper showed a significantly higher incidence of postoperative infection and infection requiring reoperation in patients who had received therapeutic injection within 7 months before TKA [15].

Our case is unique in that it shows a previously undescribed complication of viscosupplementation. We present a case of late hemorrhagic pseudoseptic arthritis encountered during TKA. Our triad of findings includes (1) acute and chronic inflammatory cells on frozen section, (2) synovitis with hemosiderin deposition, and (3) blackened cartilage with iron deposition on permanent histopathology.

Case history

A 70-year-old female presented to us with a chief complaint of right knee pain. She had previously been treated by an outside orthopaedist for knee OA with a series of 3 weekly Orthovisc (DePuy Synthes, Warsaw, IN) injections 2 months prior. There was no effusion or acute inflammatory reaction after these initial HA injections. She reports having tried acetaminophen, various nonsteroidal anti-inflammatory drugs, narcotics, and topical medications over the past 8 months. All failed to provide any relief. She relates constant, debilitating pain when walking, kneeling, and going up or down the stairs that has acutely worsened.

Her past medical history includes asthma and hyperlipidemia. Her only medication is simvastatin. She has no known medical allergies. Her social history includes infrequent alcohol use, and she is a nonsmoker.

Physical examination revealed an overweight female with a body mass index of 29 kg/m². She had an antalgic gait. The dermis overlying her right knee was intact without erythema or warmth. Her knee examination revealed a moderate effusion, diffuse tenderness to palpation, and palpable crepitation during passive range of motion. Goniometer assessment exhibited a 20° flexion contracture, and maximal flexion was limited to 90°. Strength testing limited by pain but discernibly intact for age. Mechanical alignment showed a valgus deformity. Weight bearing radiographs were obtained, which showed severe tricompartmental arthritis (Fig. 1).

Taking into consideration her history of knee injections and the severity of her symptoms, inflammatory markers were obtained to rule out infectious or other inflammatory etiology. Her white blood cell (WBC) count and C-reactive protein (CRP) were within normal limits at 5.9 × 10⁹ per liter and <0.5 mg/dL, respectively. Her erythrocyte sedimentation rate (ESR) was found to be slightly elevated at 38 mm/h. The decision was made to proceed with TKA.

In the operating room, the knee was prepped and draped in the usual sterile fashion. Preoperative antibiotics consisting of 2 grams cefazolin were administered before skin incision. A 12-cm longitudinal incision was made through the skin centered over

![Figure 1. Preoperative radiographs. Preoperative anteroposterior (AP), lateral, and merchant weight bearing views of the right knee showing severe tricompartmental arthritis.](image-url)
the patella. A medial parapatellar arthrotomy was performed, which revealed a significant effusion of purulent fluid. Marked synovitis was noted. Eversion of the patella revealed large areas of blackened articular cartilage on both the femoral condyles and underside of the patella (Fig. 2). An intraoperative pathology consult was obtained. Frozen section histopathology showed greater than 5 neutrophils per high-powered field. Specimens were obtained, and the decision was made to abort the knee replacement and instead perform an irrigation, synovectomy, and closure.

Postoperatively, the patient was placed on cefazolin for 3 days pending tissue and fluid cultures. All final cultures were negative, and antibiotics were discontinued before discharge. Postoperative inflammatory markers were obtained: WBC count 8.1 × 10^9 per liter, ESR 53 mm/h, CRP 14.1 mg/dL. Permanent histopathology showed synovial tissue with marked chronic inflammation, focal acute inflammation, and old hemorrhage. There were also abundant histiocytes containing foreign material.

Following the initial procedure, 2 months later, the patient’s inflammatory markers had normalized: WBC 6.3 × 10^9 per liter, ESR 25 mm/h, and CRP <0.5 mg/dL. An arthrocentesis was done, and the Synovasure (Zimmer) panel for native septic arthritis was negative. The patient was taken for an uncomplicated TKA 3 months postoperative (Fig. 3). Synovium, cartilage, and bone were sent to pathology for special consideration. The specimens showed proliferative synovium with brown pigment (hemosiderin) in the stroma and inflammation around foreign material (Fig. 4). Prussian blue stain showed hemosiderin (iron deposition) in the synovium and cartilage (Figs. 5 and 6). Foreign body material was seen in synovial giant cells at the various foci of inflammation (Fig. 7). This foreign body material was shown to be hyaluronate on alcian blue staining [13].

The patient was seen 2 weeks after TKA for staple removal. The incision was clean, dry, and nonerythematous. Her pain was well controlled. She was fully weight bearing and advancing well with outpatient physical therapy with improved range of motion. At the time of manuscript submission, the patient was doing well 6 months after TKA.

Discussion

There are no reports in the literature of delayed hemorrhagic pseudoseptic arthritis as a consequence of viscosupplementation. Acute inflammatory reactions to HA injection have been well described and usually begin within 48 hours of injection [10,11,16]. Our case is especially interesting because it was a late finding encountered during primary TKA, yielding the unique opportunity for laboratory testing and numerous pathology specimens.

One case series examined pathology specimens of 6 knees (5 patients) with a history of acute reactions to HA injection with complete resolution after 1-2 weeks that later underwent either arthroscopy or TKA for symptomatic OA. Surgical procedures
occurred between 2-9 months after last series of visco-supplementation. Routine histolopathologic examination revealed inflamed synovium with giant cells surrounding foreign body material. This material also stained positive with alcian blue and disappeared after hyaluronidase digestion, which is consistent with hyaluronate [11]. During the course of this study, 2 patients underwent arthroscopic debridement of the contralateral knee, which had not previously been treated with viscosupplementation. Granulomatous inflammation was not observed in either of these knees, therefore, eliminating the possibility of other systemic etiology. The study concluded that a component of viscosupplementation was likely responsible for the observed granulomatous inflammation. It was also hypothesized that this inflammation was a possible pathologic cause of intractable knee symptoms after supplementation [10].

One case report in the literature describes abnormal adipose and synovium found during TKA. The described patient had a history of 3 HA injections with the last one being 3 months before the procedure. The authors described the synovium as brown and the adipose as firm and indurated. Histologic examination of the adipose revealed granulomatous inflammation with giant cells surrounding pools of intensely basophilic material, which was presumably hyaluronate. These authors termed this reaction “Synvisc perisynovitis” and attributed it to inadvertent injection into the fat pad. Speculation as to the cause of this reaction included hyaluronan breakdown products causing an increased production of proinflammatory cytokines [17].

Our histlogic findings are similar to the above descriptions of granulomatous reactions to HA. However, our patient did not report any acute inflammatory reaction after injection. Instead, the abnormal synovium, bone, and cartilage were encountered months later during primary TKA, which caused the initial procedure to be aborted. This represents a previously unreported complication of HA.

Summary

We describe a case of late hemorrhagic pseudoseptic arthritis encountered during TKA due to HA viscosupplementation. Our triad of findings includes (1) acute and chronic inflammatory cells on frozen section, (2) synovitis with hemosiderin deposition, and (3) blackened cartilage with iron deposition on permanent histopathology. Histopathology revealed foreign body granulomatous inflammation consistent with previous reports of acute, adverse inflammatory reactions to HA. Our case is unique in that it shows a previously undescribed late complication of viscosupplementation.

Acknowledgment

The authors thank Zaida Olmo-Durham, MD, clinical assistant professor of the department of Pathology Rutgers-Robert Wood Johnson Medical School, for preparing and interpreting the pathology slides.

References

[1] Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58(1):26.
[2] Guccione AA, Felson DT, Anderson JJ, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health 1994;84(3):351.
[3] Nüesch E, Dieppe P, Reichenbach S, et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011;342:d1165.
[4] Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res 2004;(427 Suppl):56.
[5] Gabriel SE, Crowson CS, Campion ME, O’Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1997;24(4):719.
[6] Jevsevar DS, Brown GA, Jones DL, et al. The American Academy of Orthopaedic Surgeons evidence-based guideline on: treatment of osteoarthritis of the knee, 2nd edition. J Bone Joint Surg Am 2013;95(20):1885.

[7] van der Weegen W, Wullems JA, Bos E, Noten H, van Drunen RA. No difference between intra-articular injection of hyaluronic acid and placebo for mild to moderate knee osteoarthritis: a randomized, controlled, double-blind trial. J Arthroplasty 2015;30(5):754.

[8] Jevsevar D, Donnelly P, Brown GA, Cummins DS. Viscosupplementation for osteoarthritis of the knee: a systematic review of the evidence. J Bone Joint Surg Am 2015;97(24):2047.

[9] Schmajuk G, Bozic KJ, Yezydany J. Using Medicare data to understand low-value health care: the case of intra-articular hyaluronic acid injections. JAMA Intern Med 2014;174(10):1702.

[10] Roos J, Epaulard O, Juvin R, et al. Acute pseudoseptic arthritis after intraarticular sodium hyaluronan. Joint Bone Spine 2004;71(4):352.

[11] Chen AL, Desai P, Adler EM, Di Cesare PE. Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg Am 2002;84-A(7):1142.

[12] Leopold SS, Warme WJ, Petris S, Shott S. Increased frequency of acute local reaction to intra-articular hylan GF-20 (synvisc) in patients receiving more than one course of treatment. J Bone Joint Surg Am 2002;84-A(9):1619.

[13] Ottaviani RA, Wooley P, Song Z, Markel DC. Inflammatory and immunological responses to hyaluronan preparations. Study of a murine biocompatibility model. J Bone Joint Surg Am 2007;89(1):148.

[14] Bucher W, Otto T, Hamburger M. Differentiation of hyaluronic products by qualitative differences in their immunogenicity in rabbits: possible mechanism for product-specific severe adverse reactions? Comment on the article by Martens. Arthritis Rheum 2002;46(9):2543; author reply 2544.

[15] Bedard NA, Pugely AJ, Ellings JM, et al. The John N. Insall Award: Do Intraarticular Injections Increase the Risk of Infection After TKA? Clin Orthop Relat Res. 2016. http://dx.doi.org/10.1007/s11999-016-4757-8.

[16] Michou L, Job-Deslandre C, de Pinieux G, Kahan A. Granulomatous synovitis after intraarticular Hylan GF-20. A report of two cases. Joint Bone Spine 2004;71(5):438.

[17] Zardawi IM, Chan L. Synvisc perisynovitis. Pathology 2001;33(4):519.